Q3 2024 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

Nov 05, 2024 / 10:00PM GMT

Release Date Price: MXN1150.56

Transcript 10-Q8-K

Key Points

Positve

Ultragenyx Pharmaceutical Inc (RARE) reported a 42% year-over-year revenue growth for the third quarter of 2024, reaching $139 million.
The company is on track for three near-term BLA submissions and potential approvals for treatments targeting Sanfilippo Syndrome Type A, GSD1A, and osteogenesis imperfecta.
Ultragenyx has expanded its geographic access, with significant revenue contributions from Latin America, Europe, the Middle East, and Japan.
The FDA granted breakthrough therapy designation for UX143 (setrusumab) for osteogenesis imperfecta, highlighting its potential clinical benefits.
Ultragenyx has successfully launched Evkeeza in Japan and is progressing with the conditional filing package for Dojolvi, strengthening its rare disease business in the region.

Negative

Ultragenyx reported a net loss of $134 million for the third quarter of 2024, with total operating expenses reaching $271 million.
The company anticipates a net cash usage of around $400 million for the year, indicating significant cash burn.
There is variability in revenue from Latin America due to uneven ordering patterns, which could affect financial projections.
The commercialization of new therapies may require substantial investment in salesforce expansion and manufacturing capabilities.
The path to profitability is projected by the end of 2026, indicating a longer timeline before achieving financial self-sufficiency.

Operator

Good afternoon and welcome to the Ultragenyx third-quarter 2024 financial results conference call. (Operator Instructions) It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations. Thank you.

Joshua Higa

Ultragenyx Pharmaceutical Inc - Investor Relations

We've issued a press release detailing our financial results, which you can find on our website at Ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President, Erik Harris, Chief Commercial Officer, Howard Horn, Chief Financial Officer, and Eric Krondes, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC files. I'll now turn the call over to Emil.

Emil Kakkis

Ultragenyx Pharmaceutical Inc - President, Chief Executive Officer, Director

Thanks, Josh, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.